Navigation Links
OncoSec Medical Appoints Engineering Leader
Date:7/5/2011

SAN DIEGO, July 5, 2011 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today the appointment of Brian McCluskey as Executive Director, Engineering, who will lead the development of the company's proprietary electroporation delivery technology, the OncoSec Medical System (OMS).

(Logo: http://photos.prnewswire.com/prnh/20110314/MM64943LOGO)

Punit Dhillon, OncoSec's President and CEO, said, "We are pleased that Brian will join  our management team. He brings a proven track record of medical device design and technical leadership experience, with the ability to design, manage and coordinate the development of medical devices from concept to production. Brian will be instrumental in developing OncoSec's next generation OMS products."

OncoSec's minimally invasive ElectroOncology therapies utilize its proprietary electroporation delivery system, called the OncoSec Medical System (OMS), which applies short electrical impulses to selectively targeted tumors and tissue in order to significantly increase the ability of anti-cancer chemotherapeutic or biologic agents to enter into cells. These treatments selectively destroy cancer cells while preserving healthy tissue. They optimize required dosage and potentially reduce treatment and post-treatment costs.

Brian McCluskey, Executive Director, Engineering

Mr. McCluskey has more than 30 years of electrical engineering experience, in which he has spent the last 20 years developing software and hardware for devices used for medical and research purposes. Through this, he has managed successful submissions for FDA 510(k) approvals, as well as, CE marks for marketing in Europe. Mr. McCluskey was recently with Teledyne RD Instruments (TRDI), a leader in the design and manufacture of Doppler instrumentation, for which he managed custom production for TRDI clients. He was also engineering manager for Digirad Corporation, a leading manufacturer of solid-state gamma cameras and cardiology imaging software, for which he managed product development from early conception to product release leading to multi-million dollar revenue in his first year.

Mr. McCluskey will lead OncoSec's team of engineers and manufacturing operations as well as work closely with the company's Quality Assurance department.

About OncoSec Medical Inc.

OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec's clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Medical Announces the Appointment of Dr. Anthony E. Maida, III, to Its Board of Directors
2. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
3. OncoSec Medical Closes $1.1M Financing
4. OncoSec Medical to Present at ROTH 23rd Annual Growth Stock Conference
5. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
6. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
7. Ansell Limited Acquires Sandel Medical Industries LLC, an Innovator in Surgical Safety Solutions
8. Sonitus Medical Receives Second FDA Clearance for SoundBite™ Hearing System
9. Qmed Profiles Searchable Across All Medical Device Websites
10. MarketsandMarkets: Global Top 10 Medical Devices Market (2010 - 2015)
11. Global Medical Imaging Launches Worlds First Ultrasound Maintenance App
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Restoration, has recently contributed a medical article to the newly revamped Cosmetic ... Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... the nation's first interactive health literacy software tool, and the Cancer Patient Education ... of cancer patient education, today announce a new strategic alliance. , As ...
Breaking Medicine News(10 mins):